Table 1.
Baseline characteristics
| Patients with and without symptomatic menopausal transition | ||||||
|---|---|---|---|---|---|---|
| Before matching | After matching | |||||
| With SMT (n = 13,575) | Without SMT (n = 382,178) | Std. diff. | With SMT (n = 8,549) | Without SMT (n = 8,549) | Std. diff. | |
| Age (years) | ||||||
| 45–49 | 26.1 | 38.4 | 0.30 | 28.0 | 30.7 | 0.07 |
| 50–54 | 40.8 | 23.7 | 0.51 | 37.3 | 37.0 | <0.01 |
| 55–59 | 22.3 | 20.2 | 0.10 | 22.8 | 20.9 | 0.06 |
| 60–64 | 10.8 | 17.6 | 0.24 | 11.9 | 11.4 | 0.02 |
| Medical history | ||||||
| Diabetes mellitus | 3.1 | 2.3 | 0.08 | 3.4 | 3.5 | <0.01 |
| Hyperlipidaemia | 7.4 | 1.8 | 0.36 | 6.4 | 6.7 | <0.01 |
| Obesity | 1.8 | 0.3 | 0.19 | 1.8 | 1.9 | <0.01 |
| Cerebrovascular disease | 0.7 | 0.8 | 0.01 | 0.7 | 0.9 | 0.03 |
| Hypertension | 7.7 | 4.7 | 0.19 | 7.5 | 7.7 | 0.03 |
| Ischaemic heart disease | 0.9 | 0.9 | 0.02 | 1.1 | 0.9 | <0.01 |
| Renal failure syndrome | 0.7 | 0.6 | 0.03 | 0.7 | 0.5 | 0.03 |
| Chronic liver disease | 0.6 | 0.7 | 0.02 | 0.6 | 0.7 | 0.02 |
| Urinary tract infection | 0.6 | 0.3 | 0.06 | 0.5 | 0.6 | 0.04 |
| Malignant neoplastic disease | 2.9 | 3.6 | 0.02 | 2.8 | 3.1 | 0.03 |
| Medication | ||||||
| Beta-blocking agents | 4.7 | 3.9 | 0.06 | 4.3 | 4.9 | 0.06 |
| Calcium channel blocker | 5.8 | 4.5 | 0.10 | 5.6 | 5.8 | 0.02 |
| Diuretics | 5.8 | 3.6 | 0.13 | 5.5 | 5.7 | 0.01 |
| ACE inhibitors or angiotensin II antagonist | 6.1 | 3.7 | 0.18 | 5.7 | 5.7 | 0.01 |
| Anti-thrombotic agents | 8.6 | 7.5 | 0.06 | 8.1 | 8.5 | 0.01 |
| Blood glucose-lowering drugs | 3.4 | 2.5 | 0.10 | 3.6 | 3.5 | 0.02 |
| Antibacterial drugs | 22.8 | 17.8 | 0.14 | 20.7 | 22.6 | 0.07 |
Values are presented as proportion of patients (%).
Abbreviations: ACE inhibitors, angiotensin-converting enzyme inhibitors; SMT, symptomatic menopausal transition; Std. diff., standardised difference.